Hormonal
A lower omega-6 to omega-3 fatty acid ratio (specifically 4:1 or lower) reduces total mortality and cardiovascular disease risk compared to the standard Western ratio of 15:1-16.7:1.
To improve heart health and reduce inflammation, shift your diet to lower the ratio of omega-6 to omega-3 fats. Aim for a ratio of 4:1 or lower. This means eating more fatty fish (salmon, mackerel) or taking fish oil supplements, while reducing intake of oils high in omega-6 like corn, soybean, and sunflower oils. Replace these with olive oil or canola oil, which have a more favorable profile. This shift helps reduce inflammation and cardiovascular risk.
Excessive amounts of omega-6 polyunsaturated fatty acids (PUFA) and a very high omega-6/omega-3 ratio, as is found in today’s Western diets, promote the pathogenesis of many diseases, including cardiovascular disease, cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 PUFA (a lower omega-6/omega-3 ratio), exert suppressive effects.
Why this rating
The paper is a review citing multiple clinical trials (Lyon Heart Study, GISSI) and observational data, though it lacks a single large-scale RCT establishing a universal optimal ratio.
Source
The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases
Artemis P. Simopoulos · Experimental Biology and Medicine · 2008
DOI 10.3181/0711-mr-311
More from this paper
- A lower omega-6 to omega-3 ratio (specifically 2.5:1) reduces rectal cell proliferation in patients with colorectal cancer, whereas a higher ratio (4:1) with the same omega-3 amount has no effect.Moderate
- A lower omega-6 to omega-3 ratio (2-3:1) suppresses inflammation in patients with rheumatoid arthritis, and a ratio of 5:1 has a beneficial effect on asthma, whereas a ratio of 10:1 has adverse consequences.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →